Tofacitinib relieves symptoms of stimulator of interferon genes (STING)–associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173 - 19/04/17

Jieun Seo, BS ^a, ∗

  These authors contributed equally to this work.

, Jung-Ah Kang, MS ^b, ∗

  These authors contributed equally to this work.

, Dong In Suh, MD ^c, ∗

  These authors contributed equally to this work.

, Eun-Byeol Park, BS ^d, Cho-Rong Lee, MS ^b, Sun Ah Choi, MD ^c, Soo Yeon Kim, MD ^c, Yeji Kim, BS ^e, Sang-Heon Park, MS ^b, Michael Ye, PhD ^f, Soon-Hak Kwon, MD ^g, June Dong Park, MD, PhD ^c, Byung Chan Lim, MD ^c, Dong Hun Lee, MD, PhD ^e, Suk-Jo Kang, PhD ^d, Murim Choi, PhD ^{a, c} , Sung-Gyoo Park, PhD ^b , Jong-Hee Chae, MD, PhD ^c

^a Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea 

^b Cell Logistics Research Center and School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Korea 

^c Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea 

^d Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Korea 

^e Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea 

^f School of Liberal Arts and Sciences, Gwangju Institute of Science and Technology, Gwangju, Korea 

^g Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Korea